These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34814865)

  • 21. Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort.
    Rønnow SR; Langholm LL; Karsdal MA; Manon-Jensen T; Tal-Singer R; Miller BE; Vestbo J; Leeming DJ; Sand JMB
    Respir Res; 2020 Jul; 21(1):202. PubMed ID: 32731895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis.
    Kubo S; Siebuhr AS; Bay-Jensen AC; Juhl P; Karsdal MA; Satoh Y; Todoroki Y; Nakano K; Nakayamada S; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):532-539. PubMed ID: 32022479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Moll SA; Wiertz IA; Vorselaars AD; Zanen P; Ruven HJ; van Moorsel CH; Grutters JC
    Biomark Med; 2020 Jul; 14(11):997-1007. PubMed ID: 32940077
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
    Poletti V; Vancheri C; Albera C; Harari S; Pesci A; Metella RR; Campolo B; Crespi G; Rizzoli S;
    Respir Res; 2021 Feb; 22(1):66. PubMed ID: 33627105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study.
    Juhl P; Bay-Jensen AC; Karsdal M; Siebuhr AS; Franchimont N; Chavez J
    PLoS One; 2018; 13(12):e0207324. PubMed ID: 30507931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD.
    Stolz D; Leeming DJ; Kristensen JHE; Karsdal MA; Boersma W; Louis R; Milenkovic B; Kostikas K; Blasi F; Aerts J; Sand JMB; Wouters EFM; Rohde G; Prat C; Torres A; Welte T; Roth M; Papakonstantinou E; Tamm M
    Chest; 2017 Jan; 151(1):47-59. PubMed ID: 27575358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
    Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
    Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.
    Guiot J; Bondue B; Henket M; Corhay JL; Louis R
    BMC Pulm Med; 2016 May; 16(1):86. PubMed ID: 27215343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type VIII collagen is elevated in diseases associated with angiogenesis and vascular remodeling.
    Hansen NU; Willumsen N; Sand JM; Larsen L; Karsdal MA; Leeming DJ
    Clin Biochem; 2016 Aug; 49(12):903-8. PubMed ID: 27234597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.
    Karsdal MA; Hjuler ST; Luo Y; Rasmussen DGK; Nielsen MJ; Holm Nielsen S; Leeming DJ; Goodman Z; Arch RH; Patel K; Schuppan D
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G25-G31. PubMed ID: 30160980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
    Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
    Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.